Hemostemix Inc. (CVE:HEM – Get Free Report) was up 17.5% during trading on Friday . The stock traded as high as C$0.24 and last traded at C$0.24. Approximately 865,576 shares traded hands during trading, an increase of 50% from the average daily volume of 576,068 shares. The stock had previously closed at C$0.20.
Hemostemix Trading Up 20.0 %
The stock has a 50-day moving average of C$0.09 and a two-hundred day moving average of C$0.08. The firm has a market cap of C$20.91 million, a price-to-earnings ratio of -12.00 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- What Are the U.K. Market Holidays? How to Invest and Trade
- ServiceTitan Made Waves in Its IPO, But Is the Stock a Buy?
- Compound Interest and Why It Matters When Investing
- Netflix: Is This the Perfect Time to Buy a Streaming Powerhouse?
- What to Know About Investing in Penny Stocks
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
